| Autor: |
Maștaleru A; Department of Medical Specialties I, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iaşi, Romania.; Clinical Rehabilitation Hospital, 700661 Iaşi, Romania., Cojocariu SA; Department of Medical Specialties I, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iaşi, Romania.; Clinical Rehabilitation Hospital, 700661 Iaşi, Romania., Oancea A; Department of Medical Specialties I, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iaşi, Romania.; 'Saint Spiridon' County Clinical Emergency Hospital, 700111 Iaşi, Romania., Constantin MML; Department of Medical Specialties I, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iaşi, Romania.; Clinical Rehabilitation Hospital, 700661 Iaşi, Romania., Roca M; Department of Medical Specialties I, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iaşi, Romania.; Clinical Rehabilitation Hospital, 700661 Iaşi, Romania., Zota IM; Department of Medical Specialties I, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iaşi, Romania., Abdulan I; Department of Medical Specialties I, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iaşi, Romania., Rusu C; Department of Medical Genetics, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iaşi, Romania., Popescu R; Department of Medical Genetics, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iaşi, Romania., Antoci LM; Department of Medical Genetics, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iaşi, Romania., Ciobanu CG; Department of Medical Genetics, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iaşi, Romania., Costache AD; Department of Medical Specialties I, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iaşi, Romania., Cojocaru E; Department of Morphofunctional Sciences I, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iaşi, Romania., Mitu F; Department of Medical Specialties I, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iaşi, Romania.; Clinical Rehabilitation Hospital, 700661 Iaşi, Romania. |
| Abstrakt: |
(1) Background: Familial hypercholesterolemia (FH) is one of the most prevalent inherited metabolic disorders. The purpose of the study was to investigate the role in cardiovascular disease (CVD) of PAI-1 , ACE , ApoB-100 , MTHFR A1298C , and C677T . (2) Methods: From a group of 1499 patients, we included 52 patients diagnosed with FH phenotype and 17 patients in a control group. (3) Results: Most of the FH patients had multiple comorbidities compared to the control group, such as atherosclerosis (48.1% vs. 17.6%), atherosclerotic cardiovascular disease (ASCVD 32.7% vs. 11.8%), and metabolic syndrome (MetS, 40.4% vs. 11.8%). In total, 66.7% of the FH patients had PAI-1 4G/5G genotype and MetS. Between 4G/5G and 4G/4G , a statistically significant difference was observed ( p = 0.013). FH patients with ApoB R3500Q polymorphism were correlated with ASCVD ( p = 0.031). Both MTHFR C677T and A1298C polymorphisms had a significant correlation with gender, alcohol consumption, and smoking status. ACE polymorphism was associated with ATS in FH patients, statistically significant differences being observed between heterozygous and homozygous D genotype ( p = 0.036) as well as between heterozygous and homozygous I genotype ( p = 0.021). (4) Conclusions: A link between these polymorphisms was demonstrated in the FH group for ATS, ASCVD, and MetS. |
